ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Phase 1 Completed 52 enrolled AbbVie

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.

Timeline

Start: 2010-04
Primary completion: 2013-06
Completion: 2013-06

Publications

Results Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6. Epub 2015 May 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ilorasertib	Small molecule	480 mg	Oral
Subject	Ilorasertib	Small molecule	540 mg	Oral
Background	Azacitidine	Other / unclassified	—	Intravenous

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Summary

Timeline

Publications

Drugs

Indications